Vertex Pharmaceuticals is expected to report first quarter earnings on May 5, with investor focus on its two big launches and ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% ...

The non-profit Institute for Clinical and Economic Review has issued a lukewarm final evidence report on Vertex Pharmaceuticals' (NASDAQ:VRTX) non-opioid pain medicine Journavx (suzetrigine).

Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about 16% ...

Equity markets have been seesawing for the past two weeks. Stocks fell hard after President Donald Trump announced his tariff ...

Vertex Pharmaceuticals Incorporated ... of sickle cell disease and transfusion-dependent beta thalassemia; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic ...

The biopharmaceutical industry is positioned for continued recovery, driven by recent FDA approvals and billion-dollar ...

Meanwhile, for fiscal 2025, analysts expect Vertex Pharmaceuticals to report an ... and initial contributions from JOURNAVX. Furthermore, analysts' consensus view on VRTX stock is moderately ...

Casgevy and Journavx are poised to become significant growth drivers for Vertex Pharmaceuticals in the coming years, marking pivotal steps in the company's push to diversify its portfolio.

It also seems to have a knack for filling those needs, as the apparent robust demand for Journavx indicates ... for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them.